

technology includes at least two marketed products—DepoDur for controlled release of morphine and DepoCyt, an intrathecally injected sustained release anticancer product.

Some further coverage of liposomes as a dispersed pharmaceutical system is found in chapter 9.

## REFERENCES

1. <http://www.ecomm.baxter.com/ecatalog/browseCatalog.do?lid=10001&hid=10001&cid=10016&key=a17fb6d9dd83be5836e1adffd2d249f>.
2. Brown L, Qin Y, Hogeland K, et al. Water-soluble formation of monodispersed insulin microspheres. In: Svenson S, ed. *Polymeric Drug Delivery II, Polymeric Matrices and Drug Particle Engineering*, ACS Symposium Series 924. : Washington, D.C.: American Chemical Society, 2006; chap 22.
3. Dunn R. Application of ATRIGEL<sup>®</sup> implant drug delivery technology for patient-friendly, cost-effective product development. *Drug Deliv Technol* 2003; 3:38–43.
4. Harrison RC. Development and applications of long-acting injection formulations. *Drug Deliv Technol* 2006; 6:36–40.
5. Johns G, Corbo G, Thanoo BC, et al. Broad applicability of a continuous formulation process for manufacture of sustained-release injectable microspheres. *Drug Deliv Technol* 2004; 4:60–63.
6. Martini A, Lauria S. Sustained release injectable products. *Am Pharm Rev* 2003; 6(Fall):16–20.
7. Morar AS, Schrimsher JL, Chavez MD. PEGylation of proteins: A structural approach. *BioPharm Int* 2006; 19(4):34–49.
8. Reimer D, Eastman S, Flowers C, et al. Liposome formulations of sparingly soluble compounds: Liposome technology offers many advantages for formulation of sparingly soluble compounds. *Pharmaceutical Formulation and Quality*. August/September 2005:42–44.
9. Tice T. Delivering with depot formulations. *Drug Deliv Technol* 2004; 4:44–47.
10. Verrijck R, Gos B, Crommelin BJA, et al. Controlled release of pharmaceutical proteins from hydrogels. *Pharm Manuf Packing Sourcer* 2003 (Summer), 27–33.